Designing a Defensible Clinical Study with an AI Co-Pilot

I designed the M2 OPERA pilot and the ARM2 meta-analysis using this workflow. AI helped at every stage — but the judgment call that makes a study defensible to reviewers, IRBs, and editors never transferred to the model. That distinction matters more than most tutorials admit.

Why AI Speeds Up the Wrong Things

The default AI use in study design is generating an outline. That's the least valuable stage to outsource. The decisions that determine whether your study can actually answer the question happen in PICO framing, design selection, and randomization scheme. Rush those with AI and you get a well-formatted protocol with a fundamental flaw buried inside it.

The six stages below put AI where it earns its keep. Each names the prompt and the human check that can't be automated away.

Stage 1: PICO Sharpening

Feed the model your rough research question and ask it to enumerate every plausible PICO interpretation — population strata, outcome timing, comparator options, feasible follow-up durations. Don't ask it to pick one. Ask it to surface the decision space.

The human check: you select the PICO that matches your patient population, available data, and institutional capacity. The model expands the possibility space; you constrain it to what's real. This is the stage where clinical researchers are often too narrow too early — and where AI is genuinely useful as a structured prompt for scope.

Stage 2: Design Fit

Once PICO is fixed, prompt: "Given this PICO, list the study designs that could answer it, with the main assumption each design requires and the sample size implications." Claude handles common designs well — RCT, cohort, case-control, diagnostic accuracy. It underperforms on adaptive designs and platform trials.

The human check: does your context satisfy the design's core assumptions? A cluster RCT requires an ICC estimate your pilot may not have produced. Claude won't flag that gap unless you explicitly tell it the gap exists.

For red-teaming the chosen design itself — finding the holes in your protocol before reviewers do — red-teaming study design with Claude covers that systematically.

Stage 3: Sample Size

Feed the model the design narrative — not the formula — and ask it to name the statistical test, enumerate the inputs required for a power calculation, and then calculate. The failure pattern: Claude defaults to simple parallel-arm formulas and routinely misses inflation factors for clustering, non-inferiority margins, and expected dropout.

The human check: confirm the test family matches your design before accepting any numbers. If you're running a cluster trial and Claude doesn't mention ICC inflation, the calculation is wrong. A 10-minute human check here is cheaper than an underpowered study.

Stage 4: Randomization

Generate randomization code with AI, then audit three things manually: allocation concealment (can the enroller access the sequence?), stratification (does your design require balancing on a covariate?), and audit trail (who holds the schedule and when is it revealed?). I've reviewed LLM-generated R scripts for colleagues where the block size was fixed and predictable — allocation concealment silently broken.

Read the generated code before running it. Every time.

Stage 5: Reporting Standard

Ask the model to identify the relevant reporting guideline for your design (CONSORT, STROBE, STARD, PRISMA-DTA) and generate a fillable checklist. Fill it out now, before you start wrting. This surfaces any sections your design doesn't yet address — gaps you can close prospectively, before they become reviewer comments.

Reporting compliance is close to mechanical. The model handles it well; use it at this stage without hesitation. The research workflow on choosing a study design goes deeper on design taxonomy if you need to revisit the classification before this step.

Stage 6: Pre-Registration

Draft the OSF pre-registration with AI assist, but treat the analysis plan as the protected step. Over-specification locks you into subgroup tests you weren't powered to run. Under-specification gives reviewers ammunition to dismiss your results as exploratory.

Prompt: "Draft an OSF analysis plan for this design. Flag anywhere you're making assumptions I haven't confirmed." Then push back on every flagged assumption before registering. Register before data collection — that part isn't negotiable and AI can't make the decision for you.

---

The Research Mentor tools at aiforacademic.world — Validate idea and Generate outline (PICO) — cover stages 1 and 2 in a single Workspace session, chaining PICO sharpening to outline generation without losing context between steps. If you're working through this workflow under time pressure, that context persistence is worth more than it sounds.

What "Defensible" Actually Means

When I say defensible, I mean a study that can survive three different kinds of scrutiny. First, the clinical question has to matter enough that the population, comparator, and endpoint are not arbitrary. Second, the method has to match the question closely enough that the design does not smuggle in avoidable bias. Third, the reporting has to make your choices legible to someone who was not in the room when the protocol was written.

AI helps most when the work is still structured but not yet fixed. That is why I use it for framing, surfacing alternatives, and checking completeness. I do not use it to make the final call on inclusion criteria, sample size assumptions, or analysis boundaries. If I let the model make those calls, I may get a fluent draft, but I do not get a defensible study.

This distinction matters in real projects. In the M2 OPERA pilot, I needed fast movement between question refinement, feasibility checks, and protocol wording. In the ARM2 meta-analysis, the same workflow helped me keep the search logic, selection criteria, and reporting expectations aligned. The speed came from AI; the rigor came from keeping the human in charge of the irreversible decisions.

Failure Modes I Watch For

The first failure mode is false precision. The model will happily give you a number, a cutoff, or a sequence that looks mathematically tidy even when one input is not grounded in your setting. I treat any clean-looking answer as provisional until I can identify the assumption beneath it.

The second failure mode is design drift. This happens when the question starts as one thing and ends as another because the model found a more convenient formulation. For example, a feasibility question can slowly morph into an efficacy study if you let the output drive the protocol. I check for that drift explicitly by comparing the original clinical intent against the final design.

The third failure mode is scope creep in the analysis plan. If the pre-registration starts accumulating too many optional branches, subgroup paths, and sensitivity tests, the protocol becomes harder to defend and easier to misread later. I prefer fewer committed analyses and a clear rationale for why those are the ones that matter.

The fourth failure mode is tool overuse. A model can produce an impressive amount of text, which tempts people to skip the hard part: deciding whether the study is actually answerable. More text is not more validity. Sometimes the best use of AI is to reveal that a concept is not ready yet.

A Compact Human Checklist

Before I treat a study as ready, I want five questions answered in plain language.

1. What exact claim will this study support, and what claim will it not support?
2. Which design is the weakest acceptable design for that claim?
3. What assumption, if wrong, would invalidate the result fastest?
4. What reporting guideline and what analysis plan match the design?
5. If a reviewer asks for one sentence of justification for each major choice, can I give it without improvising?

If I cannot answer those cleanly, I am not ready to publish the protocol, and I am definitely not ready to let the model do the writing on autopilot.

How I Use the Prompting Layer

The most useful prompts are not the ones that ask the model to be smart. They are the ones that ask the model to be explicit. I want it to list alternatives, identify missing inputs, and show the weakest point in the plan. That makes the output easier to audit and easier to reject when needed.

For example, a good design prompt is not "Write the best study design." A better prompt is "Given this clinical question, list the feasible designs, the key assumption for each, the minimum data I need, and the reason each design could fail." That framing forces the model to operate like a structured assistant rather than a decision-maker.

The same principle applies to sample size. Instead of asking for a power calculation immediately, I ask the model to name the statistical test, the effect size parameter, and the inflation or correction factors I may need. That sequence reduces the chance that I accept a clean but incomplete answer.

Why This Workflow Is Worth Keeping

I keep returning to this workflow because it scales across project types. It works for a pilot, for a meta-analysis, for a cross-sectional study, and for a protocol that may later need IRB review. The details change, but the discipline does not: separate the model's speed from the human's responsibility.

That is also why the workflow belongs inside a product. The point is not to sell "AI-written research." The point is to package a defensible sequence of checks that reduces avoidable mistakes. If a clinician can move faster without weakening the study, the tool is doing real work.

If you want to use this inside your own project, start with the two most time-saving entry points on aiforacademic.world: Validate idea and Generate outline. Those are useful because they keep the early-stage work compact. Once the question and outline are stable, move back to the manual checks in stages 3 through 6.

The short version is simple: let AI widen the map, but keep the human in charge of the route. That is the line between a fast draft and a study you can defend.